These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36074989)

  • 21. [Sacubitril-valsartan should also be the first choice to be evaluated in the elderly patient with heart failure with reduced ejection fraction].
    Camafort M; Formiga F
    Rev Esp Geriatr Gerontol; 2021; 56(2):67-68. PubMed ID: 33526274
    [No Abstract]   [Full Text] [Related]  

  • 22. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    Sinha A; Patel RB
    Eur J Heart Fail; 2023 Jan; 25(1):95-97. PubMed ID: 36445011
    [No Abstract]   [Full Text] [Related]  

  • 24. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
    Claggett B; Packer M; McMurray JJ; Swedberg K; Rouleau J; Zile MR; Jhund P; Lefkowitz M; Shi V; Solomon SD;
    N Engl J Med; 2015 Dec; 373(23):2289-90. PubMed ID: 26630151
    [No Abstract]   [Full Text] [Related]  

  • 25. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Voordes GHD; Heerspink HJL; Ter Maaten JM
    Eur J Heart Fail; 2022 May; 24(5):804-806. PubMed ID: 35415946
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
    Dereli S; Kılınçel O; Çerik İB; Kaya A
    Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
    Briasoulis A; Kuno T; Ueyama H
    Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504
    [No Abstract]   [Full Text] [Related]  

  • 30. Utilization of Sacubitril/Valsartan in Real-World Settings.
    Eworuke E; Menzin TJ; Welch EC; Kolonoski J; Huang TY
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):619-623. PubMed ID: 32839953
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter to the Editor regarding to 'Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control'.
    Wewer Albrechtsen NJ; Bojsen-Møller KN
    Int J Cardiol; 2022 Dec; 368():55. PubMed ID: 36037929
    [No Abstract]   [Full Text] [Related]  

  • 32. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Crea F
    Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264
    [No Abstract]   [Full Text] [Related]  

  • 34. Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis.
    Dai W; Luo J; Huang X
    Medicine (Baltimore); 2022 Jun; 101(23):e29149. PubMed ID: 35687770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
    Charuel E; Menini T; Bedhomme S; Pereira B; Piñol-Domenech N; Bouchant S; Boussageon R; Bœuf-Gibot S; Vaillant-Roussel H
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00844. PubMed ID: 34617669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive Recommendation for Angiotensin Receptor-Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction.
    Howlett JG
    Can J Cardiol; 2021 Apr; 37(4):528-530. PubMed ID: 33484837
    [No Abstract]   [Full Text] [Related]  

  • 39. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 40. Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction.
    Belarte-Tornero LC; Mojón D; Solé-González E; Ruiz-Bustillo S; Valdivielso-More S; Farré N
    Rev Esp Cardiol (Engl Ed); 2021 Dec; 74(12):1117-1119. PubMed ID: 34247968
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.